

Attendance

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Call to Order: 5:02 pm**Approval of Minutes**

Discussion	Action
February minutes – votes	8 Votes - accepted
Old Business: - Electronic Honoraria payment is an option now. Please let [REDACTED] know if that is something that is wanted she can send the form to get completed. - Results of the ad-hoc vote: - New Products – “may add” for all products - Jaypirca (pirtobrutinib) tablet - Orserdu (elecestrant) tablet - New Indications – “no change” to the current formulary status - Brkinsa (zanubrutinib) caps - Keytruda (pembrolizumab) IV - Mekinist (trametinib) tabs & soln - Opdivo (nivolumab) IV - Padcev (enfortumab vedotin-ejfv) IV - Tafinlar (dabrafenib) caps & tabs - Trodely (sacituzumab govitecan-hziy) IV - Tukysa (tucatinib) tabs - Verzenio (abemaciclib) tabs - Yervoy (ipilimumab) IV	No Discussion
New Business: None	

New Products

Drug Name	Decision	Discussion	Vote Count
	All Lines of Business (Where applicable)		

Altuviiiio [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] IV	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Omisirge (omidubicel-only) IV	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Daybue (trofinetide) oral soln	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Brenzavvy (bexagliflozin) tablet	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Zavzpret (zavegepant) nasal spray	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Lamzede (velmanase alfa-tycv) IV	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Rezzayo (rezafungin) IV	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Jesduvroq (daprodustat) tablet	☐ Must Add ☒ May Add ☐ Do Not Add	██████████ asked about the wide range in the dosing and the potential rationale. ██████████ responded that the average dose in the study was 6mg and certain circumstances required different doses based on the population needing to be treated.	Must Add- 0 May Add- 12 Do Not Add- 0
Filspari (sparsentan) tablet	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Skyclarys (omaveloxolone) capsule	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Joenja (leniolisib) tablet	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0

Abbreviated New Products

Drug Name	Decision	Discussion	Vote Count
	All Lines of Business (Where applicable)		
Airsupra (albuterol/budesonide) inhalation	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0

Atorvaliq (atorvastatin) suspension	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Austedo XR (deutetrabenazine) tablet	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Combogesic (acetaminophen and ibuprofen) tablet	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Dapzura RT (daptomycin in sodium chloride) IV	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Mekinist (trametinib) oral soln	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Prevduo (neostigmine/glycopyrrolate) IV	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
RizaFilm (rizatriptan) oral film	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Rykindo (risperidone) IM	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Syfovre (pegcetacoplan) IV/intravitreal	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Tafinlar (dabrafenib) tabs for suspension	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) granules	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Udenyca (pegfilgrastim) injection	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Vowst (fecal microbiota spores, live-brpk) capsules	☐ Must Add ☒ May Add ☐ Do Not Add	[REDACTED] asked about the indication for this new product. [REDACTED] responded it was for recurrent C.dif.	Must Add- 0 May Add- 12 Do Not Add- 0

Yusimry (adalimumab-aqvh) SQ	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Zejula (niraparib) 100, 200, 300mg tablet	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0

New FDA Indications			
Drug Name	Decision	Discussion	Vote Count
	All Lines of Business (Where applicable)		
Amjevita (adalimumab-atto) SQ	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Cibinqo (abrocitinib) tab	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Cyltezo (adalimumab-adbm) SQ	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Evkeeza (evinacumab-dgnb) IV	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Eylea (aflibercept) injection	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Kevzara (sarilumab) SQ	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Livmarli (maralixibat) oral soln	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Odactra (house dust mite allergen extract) SL tab	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Polivy (polatuzumab vedotin) IV	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Qulipta (atogepant) tab	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Revatio (sildenafil) tab	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Takhzyro (lanadelumab-flyo) SQ	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Tepezza (teprotumumab-trbw) IV	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) tab/packet	☒ No Change ☐ Change	None	No Change- 12 Change- 0

Yusimry (adalimumab-aqvh) SQ	☒ No Change ☐ Change	None	No Change- 12 Change- 0
------------------------------	--	------	----------------------------

DURs			
	Discussion		
Medicare	None		
PA Medicaid			
DE Medicaid			

Formulary Review & Revisions				
PA Medicaid				
Drug Name	Recommendation	Decision	Discussion	Vote Count
None	Add to formulary	☒ Add ☐ Do Not Add	None	Add- 12 Do Not Add-0

Formulary Review & Revisions				
DE Medicaid				
Drug Name	Recommendation	Decision	Discussion	Vote Count
None	Add to formulary	☒ Add ☐ Do Not Add	None	Add- 12 Do Not Add-0

Formulary Review & Revisions				
Medicare				
Drug Name	Recommendation	Decision	Discussion	Vote Count
Austedo Titration Kit, Dayvigo, Gemtesa, Lumakras 320mg, Lupron Depot-Ped (3 month) Kit 30 mg, Lupron Depot-Ped (6-month) Kit 45 mg, Rotarix, sodium oxabate (generic Xyrem)	Add to formulary 2023	☒ Add ☐ Do Not Add	None	Add- 12 Do Not Add- 0
none	Remove from formulary 2023	☒ Remove ☐ Do Not Remove	None	Remove- 12 Do Not Remove-0

Budesonide/formoterol, Dayvigo, Dulera, fingolimod, fluticasone/salmeterol, Gemtesa, Kesimpta, Mayzent, Mounjaro, sodium oxabate, Uptravi, Verquvo, Wixela Inhub	Add to formulary 2024	☒ Add ☐ Do Not Add	None	Add- 12 Do Not Add- 0
Advair Diskus, Alphagan-P, Belsomra, Meperidine IV, Noxafil suspension, Rebif, Symbicort, Viibryd Starter Pack, Xyrem, Zytiga	Remove from formulary 2024	☒ Remove ☐ Do Not Remove	████████ commented on the removal of meperidine. He was surprised it was still being made.	Remove- 12 Do Not Remove-0

Policies**Medicare Part D (pharmacy)**

Policy Name	New/Revision	Decision (vote is for all new and revised policies)	Discussion
- Daybue (trofinetide) - Empaveli (pegcetacoplan) - Fingolimod - GLP-1 Receptor Agonists - Leniolisib (Joenja) - Ofatumumab (Kesimpta) - Omaveloxolone (Skyclarys) - Oral Benzodiazepines - Polypharmacy – Multiple ACH - Polypharmacy – Multiple CNS - Selexipag (Uptravi) - Siponimod (Mayzent) - Vericiquat (Verquvo)	☒ New Policy ☐ Policy Revision	☒ Approve as Written ☐ Do Not Approve as Written	None

• Ambrisentan (Letairis) • Armodafinil (Nuvigil) • Avatrombopag (Doptelet) • Belimumab (Benlysta) IV • Bosentan (Tracleer) • Dextromethorphan-quinidine (Neudexta) • Elexacaftor/tezacaftor/ivacaftor (Trikafta) • Eltrombopag (Promacta) • Ivacaftor (Kalydeco) • Ixekizumab (Taltz) • Lumacaftor/ivacaftor (Orkambi) • Macitentan (Opsumit) • Maralixibat (Livmarli) • Modafinil (Provigil) • Nintedanib (Ofev) • Nitroglycerin (Rective) ointment • Odevixibat (Bylvay) • Oncology Medications • Pirfenidone (Esbriet) • Posaconazole (Noxafil) • Riociguat (Adempas) • Risankizumab-rzaa (Skyrizi) • Satralizumab-mwge (Enspryng) • Sildenafil citrate (Revatio) • Sodium oxybate (Xyrem) • Tadalafil (Adcirca) • Upadacitinib (Rinvoq)	☐ New Policy ☒ Policy Revisions	☒ Approve as Written ☐ Do Not Approve as Written	None
Medicare Part B (medical)			
Briumvi (ublituximab-xiyy)	☒ New Policy ☐ Policy Revision	☒ Approve as Written ☐ Do Not Approve as Written	None
• Enspryng (satralizumab-mwge) • Eylea (aflibercept) • Lucentis (ranibizumab) • Susvimo (ranibizumab) • Tepezza (teprotumumab-trbw) • Uplizna (inebilizumab-cdon)	☐ New Policy ☒ Policy Revisions	☒ Approve as Written ☐ Do Not Approve as Written	None
Medicare Operational Policies			
• Drug Management Program • Drug Utilization Management Programs • Part D Reporting Submissions • Pharmacy & Therapeutics	☐ New Policy ☒ Policy Revision	☒ Approve as Written ☐ Do Not Approve as Written	None

Policies			
PA Medicaid			
Policy Name	New/Revision	Decision (vote is for all new and revised policies)	Discussion
- Daybue (trofinetide) - Filspari (sparsentan) - Skyclarys (omaveloxolone)	☒ New Policy ☐ Policy Revision	☒ Approve as Written ☐ Do Not Approve as Written	None
- C5b and C3 Complement inhibitors - Enspryng and Uplizna - Givlaari - Luxturna - Oncology Medications, IV/Injectable - Qbrexza - Quantity Limits - Rituxan and rituximab biosimilars - Sandostatin LAR Depot - Somatuline Depot - Tepezza - Vyvgart	☐ New Policy ☒ Policy Revisions	☒ Approve as Written ☐ Do Not Approve as Written	None
Uplizna (inebilizumab-cdon)	☒ Retire	☒ Approve Retirement ☐ Do Not Approve Retirement	None
PA Medicaid Operational Policies			
- Prior Authorization of Drugs - Formulary Management - PBM Oversight	☐ New Policy ☒ Policy Revisions	☒ Approve as Written ☐ Do Not Approve as Written	None

Policies			
DE Medicaid			
Policy Name	New/Revision	Decision (vote is for all new and revised policies)	Discussion
- Daybue (trofinetide) - Filspari (sparsentan) - Skyclarys (omaveloxolone)	☒ New Policy ☐ Policy Revision	☒ Approve as Written ☐ Do Not Approve as Written	None

• Austedo and Ingrezza • Botulinum Toxins • C5b and C3 Complement inhibitors • Cytokine and CAM Antagonists • Duplicate Therapy • Enspryng and Uplizna • Erythropoiesis Stimulating Agents • Givlaari • IV/Injectable Iron Medications • Leuprolide acetate • Luxturna • Macular Degeneration Agents • Ocular Rho Kinase Inhibitors • Oriahnn and Myfembree • Orilissa • Qbrexza • Quantity Limits • Restasis • Sandostatin LAR Depot • Somatuline Depot • Supprelin LA • Tepezza • Testosterone • Vyvgart • Zoladex	☐ New Policy ☒ Policy Revisions	☒ Approve as Written ☐ Do Not Approve as Written	None
• GCSF's • Herceptin • Inhaled Corticosteroid LABA Combination Medications • Makena (hydroxyprogesterone caproate injection) • Uplizna (inebilizumab-cdon)	☒ Retire	☒ Approve Retirement ☐ Do Not Approve Retirement	None
DE Medicaid Operational Policies			
None	☒ New Policy ☐ Policy Revision	☒ Approve as Written ☐ Do Not Approve as Written	None

Final Discussion

None

Next Meeting Date: August 3, 2023

Time Meeting Adjourned: 5:33 pm

[REDACTED]

CONFIDENTIAL